NCT04866641 2025-05-30
Safety and Tolerability Study for T-1201 Injection 100 mg Kit in Patients With Advanced Solid Tumors
Taivex Therapeutics Corporation
Phase 1 Recruiting
Clinical Trials
26 trialsNCT03078361 2023-01-11
Latinos CARES (Colorectal Cancer Awareness, Research, Education and Screening)
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Completed
NCT03078348 2022-11-09
IACCT
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Completed
NCT00373217 2022-09-21
Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
University of Virginia
Phase 2 Terminated
NCT01804179 2022-09-10
Colorectal Cancer Awareness, Research, Education and Screening (CARES)
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Completed
NCT03041701 2022-04-14
Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT04275960 2020-12-29
Study in Healthy Adult Male Participants to Gather Information How the Human Body Absorbs, Distributes and Excretes the Study Drug Selitrectinib Including the Effect of the Interaction of Food With the Study Drug on the Human Body
Bayer
Phase 1 Completed
NCT00681993 2019-01-22
PBIC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase NA Completed
NCT01753713 2017-12-12
Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00555724 2017-01-09
Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors
Biogen
Phase 1 Completed
NCT01515969 2016-07-12
Phase 1 Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer (NSCLC)
Stanford University
Phase 1 Terminated
NCT01588301 2014-09-12
APACHE-2
University Hospital, Tours
Phase EARLY_PHASE1 Completed
NCT00956436 2013-09-16
Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC)
Biogen
Phase 1 Completed
NCT00970580 2013-09-16
A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer
Biogen
Phase 1 Completed
NCT00633724 2013-08-15
Multiple-Vaccine Therapy in Treating Patients With Non-small Cell Lung Cancer
Fukushima Medical University
Phase 1 Completed
NCT00874588 2013-08-15
Peptide Vaccine Targeting to Cancer Specific Antigen Combined With Anti-angiogenic Peptide Antigen in Treating Patients With Non-small Cell Lung Cancer
Fukushima Medical University
Phase 1 Completed
NCT00632333 2011-07-21
Combination of Chemoradiation Therapy and Epitope Peptide Vaccine Therapy in Treating Patients With Esophageal Cancer
Teikyo University
Phase 1 Unknown
NCT01266707 2010-12-24
Antiangiogenic Peptide Vaccine Therapy in Treating Patient With Hepatocellular Carcinoma
Fukushima Medical University
Phase 1 Unknown
NCT01266720 2010-12-24
HLA-A*0201 Restricted Peptide Vaccine Therapy With Gemcitabine With Gemcitabine in Patient Pancreatic Cancer (Phase1)
Fukushima Medical University
Phase 1 Unknown
NCT00677287 2009-12-29
Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Colorectal Cancer
Tokyo University
Phase 1/2 Terminated
NCT00677612 2009-12-29
Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Colorectal Cancer
Tokyo University
Phase 1/2 Terminated
NCT00681252 2009-11-19
Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Gastric Cancer
Tokyo University
Phase 1/2 Completed
NCT00681421 2009-11-19
Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Esophageal Cancer
Tokyo University
Phase 1/2 Completed
NCT00681577 2009-11-19
Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Gastric Cancer
Tokyo University
Phase 1/2 Completed
NCT00683358 2009-05-07
Human Leukocyte Antigen-A*2402-Restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer
Tokyo University
Phase 1/2 Unknown
NCT00561275 2008-07-15
Safety Study of Multiple Peptide Vaccine to Esophageal Cancer
Japanese Foundation for Cancer Research
Phase 1 Completed